Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.29
+0.33190.95%
Post-market: 35.290.00000.00%16:10 EDT
Volume:227
Turnover:8K
Market Cap:16.58M
PE:- -
High:35.30
Open:35.30
Low:35.29
Close:34.96
52wk High:37.90
52wk Low:28.87
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.09
T/O Rate:0.05%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Traditional Chinese Medicine Firm Secures Regulatory Approval for New Depression Treatment

Stock News
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

Guizhou-Based Firm Earns National Recognition for Veterans Support Efforts

Deep News
·
Sep 04

China Galaxy Securities Forecasts High-Growth Prospects in Innovative Drug Sector Driven by Commercialization and Out-Licensing Deals

Stock News
·
Sep 04

Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...

Dow Jones
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Reuters
·
Sep 04

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03